Our world-class experts. Your child’s care team.
Exceptional science. Innovative cures.
Science & medicine news
-
Chemoimmunotherapy dramatically improved survival of high-risk neuroblastoma patients
St. Jude phase II clinical trial results suggest monoclonal antibody hu14.18K322A could help change treatment of children with high-risk neuroblastoma.
-
St. Jude at ASH: Annual hematology meeting highlights recent research
Researchers will present their work and share their expertise at ASH2021, the 63rd annual meeting of the American Society of Hematology.
-
Exhaustion affects CAR T–cell clinical response
Clinical trial data reveals what controls the staying power of T cells, affecting immunotherapy responses. St. Jude scientists' findings were published in Cell Reports.
-
Findings reveal new mechanism of activation for ALK
St. Jude Children’s Research Hospital scientists have shed light on the way ligands bind to and activate ALK, an important target for cancer drug development.
-
Discovery of how immune cells sense nutrients offers new therapeutic insight
St. Jude scientists map nutrient-dependent signaling in T cells, offering possible new drug targets for treating infectious diseases, cancer and immune-mediated disorders.
-
Target prevents T-cell exhaustion, boosts CAR T–cell responses
Findings from St. Jude Children’s Research Hospital show how epigenetic regulation by the enzyme DNMT3A controls T-cell exhaustion providing a target for improving CAR T–cell immunotherapy.